FDA approval for gene therapy follows a two-gate path. A sponsor first files an Investigational New Drug application so human trials can begin, then files a Biologics License Application showing the product is safe, pure and potent. The Center for Biologics Evaluation and Research, known as CBER, runs both reviews. Expedited programs can shorten the timeline, and several draft guidances issued between September 2025 and August 2026 point to more flexibility for rare diseases. This article covers US federal law and was checked on October 10, 2026.

Why gene therapy is regulated as a biologic

FDA describes gene therapy as a technique that modifies a person’s genes to treat or cure disease. It may replace a faulty gene with a working copy, switch off a gene that is misfiring, or add a new or modified gene. Products can be plasmid DNA, viral vectors, bacterial vectors, gene editing tools or patient-derived cells. Some are given directly into the body (in vivo); others change a patient’s cells in the lab and return them (ex vivo).

All of these are biological products under CBER. The agency’s page says human studies in the US need an IND before they start and that marketing requires a BLA. The legal anchor for the licence is section 351 of the Public Health Service Act, codified at 42 U.S.C. 262, which bars introducing a biological product into interstate commerce without a biologics licence and directs approval only when the applicant shows the product is “safe, pure, and potent” and the manufacturing facility meets standards to keep it so.

The path in six steps

  1. Lab and animal work. Developers build the vector or editing tool, test it in cells and animals, and prepare manufacturing and safety data.
  2. IND submission. Under 21 CFR 312.40, an IND takes effect 30 days after FDA receives it unless FDA places the study on clinical hold. FDA can also clear it sooner.
  3. Phase 1. The regulation describes this as the first introduction into humans, generally 20 to 80 participants, aimed at how the body handles the product and early side effects.
  4. Phase 2. Controlled studies in patients, usually no more than several hundred, to look at whether it works and what short-term risks appear.
  5. Phase 3, or an alternative. Larger trials, from several hundred to several thousand people, are the usual model. Many gene therapies treat conditions so rare that such trials are impossible, which is where the flexibilities discussed below come in.
  6. BLA review. The sponsor submits clinical, nonclinical and manufacturing data. FDA also inspects the facility. If the standard is met, FDA licences the product, often with commitments to continue collecting data after approval.

Phases usually run in order but can overlap, per the regulation.

Expedited programs that apply to gene therapy

FDA’s patient-facing page describes four general programs for serious conditions. Fast track helps develop and speeds review of drugs for serious conditions with unmet need. Breakthrough therapy targets drugs that may substantially improve on available treatment. Accelerated approval allows approval on a surrogate endpoint, a stand-in measure rather than a direct clinical outcome. Priority review sets an FDA goal of acting within six months.

Gene therapy has a fifth, specific route: regenerative medicine advanced therapy, or RMAT, designation. It was created by section 3033 of the 21st Century Cures Act, which added section 506(g) to the FD&C Act. To qualify, a product must be a regenerative medicine therapy, intended to treat a serious or life-threatening condition, and supported by preliminary clinical evidence that it could address an unmet need. FDA states that certain human gene therapies may meet the definition. A sponsor requests designation with an IND or as an IND amendment, and FDA’s tissues and advanced therapies office answers within 60 calendar days. FDA will not grant it while the IND is on clinical hold.

Program Core idea Notes for gene therapy
Fast track Faster development and review for serious conditions Available when the criteria are met
Breakthrough therapy Possible substantial improvement over existing options Available when the criteria are met
Accelerated approval Approval on a surrogate endpoint FDA’s guidance covers how Cures Act provisions apply to RMAT products
Priority review FDA goal of six months Standard review length not covered on the page I read
RMAT Regenerative medicine designation under the Cures Act Request with an IND; 60-day FDA response

What changed recently

FDA’s cellular and gene therapy guidance page shows a run of documents from the past year. All the draft items are marked non-binding and “not for implementation,” which means they signal direction but are not final rules. Here is the list as shown on the page I read on October 10, 2026.

The plausible mechanism framework is the item that most changes how people talk about approval. The draft covers individualized therapies and describes the nonclinical, clinical and manufacturing data FDA would look at to support approval or licensure for a specific indication. Both CBER and the drug center issued it. I did not find any text in the page I read that sets a new statutory pathway; it is guidance about evidence, and the legal standard of safe, pure and potent, or safe and effective for drugs, stays in the statute.

After approval: follow-up and the product list

Approval is not the end of the file. FDA’s 2020 final guidance on long-term follow-up after administration of human gene therapy says not all gene therapy products require long-term follow-up observations and tells sponsors to assess risk on listed factors, with post-licensure plans for products that pose long-term risks. The 2025 postapproval draft adds to that picture.

As of its September 17, 2026 update, FDA’s approved cellular and gene therapy products page lists 54 products in total, a count that includes cell therapies. Gene therapies on that list include Luxturna, Zolgensma, Hemgenix and Casgevy, among others.

Why manufacturing sits at the centre of the file

With a small pill, the chemistry is the easy part to describe. With a gene therapy, the product is a living or biologically derived system, and small changes in how a vector is grown, purified or filled can change how it behaves in the body. That is why the licence standard in the statute pairs the product with the facility, and why FDA’s May 2026 final guidance on chemistry, manufacturing and controls flexibilities for BLA-stage products matters to sponsors. A clinical hold on an IND can also stop the work cold: FDA will not grant RMAT designation while a hold is in place, and an IND does not take effect on the 30-day default if FDA has imposed one.

What patients and families can take from this

The pathway is long on purpose. An IND opens the door to testing in people, and a licence follows only after FDA concludes the evidence and manufacturing support it. If you are considering a trial, ClinicalTrials.gov and the treating specialist are better guides than press announcements about “approval is coming.” Routes to unapproved therapies outside trials, such as expanded access, are a separate legal track.

Related questions

Does every gene therapy need a Phase 3 trial?

Not necessarily. FDA’s 2025 draft on trial designs for small populations signals openness to alternatives where large trials are not feasible, but the draft is non-binding and the BLA standard still applies.

Is a gene therapy approved forever once licensed?

A licence stays in effect subject to FDA’s authority to suspend or revoke it and to order recalls for imminent or substantial hazards under 42 U.S.C. 262. Sponsors also face post-licensure follow-up obligations when risks warrant.

Who pays?

Coverage is a separate question from approval and not addressed by the sources I read. This is general information, not legal or medical advice.

Sources